Related references
Note: Only part of the references are listed.Commentary: SARS-CoV-2 vaccines and cancer patients
C. Corti et al.
ANNALS OF ONCOLOGY (2021)
Mortality in hospitalized patients with cancer and coronavirus disease 2019: A systematic review and meta-analysis of cohort studies
Aakash Desai et al.
CANCER (2021)
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Merryn Voysey et al.
LANCET (2021)
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
Tiziano Barbui et al.
LEUKEMIA (2021)
Looking beyond COVID-19 vaccine phase 3 trials
Jerome H. Kim et al.
NATURE MEDICINE (2021)
Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited
Antoni Ribas et al.
CANCER DISCOVERY (2021)
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study
Akshay Sharma et al.
LANCET HAEMATOLOGY (2021)
Association of the COVID-19 Outbreak With Patient Willingness to Enroll in Cancer Clinical Trials
Mark E. Fleury et al.
JAMA ONCOLOGY (2021)
Management of Unilateral Axillary Lymphadenopathy Detected on Breast MRI in the Era of COVID-19 Vaccination
Christine E. Edmonds et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2021)
The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate
M. C. Garassino et al.
ANNALS OF ONCOLOGY (2021)
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Yanjun Zhang et al.
LANCET INFECTIOUS DISEASES (2021)
SARS-CoV-2 vaccination and phase 1 cancer clinical trials
Timothy A. Yap et al.
LANCET ONCOLOGY (2021)
COVID-19 vaccination: the VOICE for patients with cancer
Astrid A. M. van der Veldt et al.
NATURE MEDICINE (2021)
Association of Social and Demographic Factors With COVID-19 Incidence and Death Rates in the US
Monita Karmakar et al.
JAMA NETWORK OPEN (2021)
Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area
Safiya Richardson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
Nicole M. Kuderer et al.
LANCET (2020)
Association of the Coronavirus Disease 2019 (COVID-19) Outbreak With Enrollment in Cancer Clinical Trials
Joseph M. Unger et al.
JAMA NETWORK OPEN (2020)
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
Denis Y. Logunov et al.
LANCET (2020)
COVID-19 and Cancer: Lessons From a Pooled Meta-Analysis
Aakash Desai et al.
JCO GLOBAL ONCOLOGY (2020)
Optimal Timing of Influenza Vaccination During 3-Week Cytotoxic Chemotherapy Cycles
Bhumsuk Keam et al.
CANCER (2017)
Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: The Role of Desensitizations
Mariana Castells
FRONTIERS IN IMMUNOLOGY (2017)
2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
Lorry G. Rubin et al.
CLINICAL INFECTIOUS DISEASES (2014)